Novartis Investigative Site

Prague, CZE 180 81

0 studies enrolling now · 5 studies all time

What they study most

Atherosclerosis, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Moderate to Severe Chronic Plaque-Type Psoriasis, Moderate to Severe Plaque-type Psoriasis

Studies at this site

• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens — Completed